title: Targeting the American market for medicines, ca. 1950s-1970s: ICI and Rhône-Poulenc compared.
abstract: The forces that have shaped American medicine include a wide set of interrelated changes, among them the changing research, development, and marketing practices of the pharmaceutical industry. This article compares the research and development (R&D) and marketing strategies of the British group Imperial Chemical Industries (ICI, whose Pharmaceutical Division was spun off and merged with the Swedish company Astra to form AstraZeneca) and its French counterpart Rhône-Poulenc (now part of Sanofi-Aventis) in dealing with the American medical market. It examines how, in the process, the relationship between R&D and marketing was altered, and the firms themselves were transformed. The article also questions the extent to which their approaches to this market, one of the most significant markets for drugs in general, and for anticancer drugs in particular, became standardized in the period of "scientific marketing."
authors.forename: Viviane
authors.initials: V
authors.lastname: Quirke
mesh_terms: D002170:Canada; D004345:Drug Industry / Q000266:history* / Q000458:organization & administration; D049673:History, 20th Century; D040541:Marketing / Q000266:history* / Q000458:organization & administration; D012106:Research / Q000266:history* / Q000458:organization & administration; D014481:United States